(FRAN) Michael W. Barnes Named Chairman, President, and CEO

Company Announces Preliminary Fiscal Third Quarter Results; Expects Net Sales of Approximately $87 Million, Comparable Store Sales Decrease of 6%, and Diluted Earnings Per Share of $0.17

HOUSTON, Dec. 5, 2014  — Francesca’s Holdings Corporation (Nasdaq:FRAN) today announced that specialty retailing veteran Michael W. Barnes has been named Chairman, President, and Chief Executive Officer, effective immediately. He succeeds Neill Davis, who has resigned as President, CEO and a Director. Greg Brenneman, Chairman of the Board since 2010, has been named Lead Director.

Mr. Barnes joins francesca’s after serving as Chief Executive Officer of Signet Jewelers, Ltd. (NYSE:SIG) since 2011. He led Signet’s $1.46 billion acquisition of Zale Corp., which transformed Signet into the largest specialty jewelry retailer in the U.S., U.K. and Canada with approximately 3,500 retail outlets. Signet’s share price almost tripled during Mr. Barnes nearly four-year tenure. Prior to Signet, Mr. Barnes spent more than 25 years in increasingly senior roles at global consumer fashion accessory company Fossil Group, Inc., concluding in the role of President, Chief Operating Officer and a Director from 2007 to 2010. As one of Fossil’s first employees, he was part of the management team that took the Company public and led the rapid profitable growth of the business.

Mr. Brenneman said, “Mike Barnes is a world-class retail executive with a proven history of driving growth at specialty retailing businesses. His ability to set and execute transformational strategic plans, along with his track record of creating value for shareholders, make him the right executive to capitalize fully on francesca’s solid growth platform.  We are confident that he has the vision and skill set to make francesca’s one of America’s leading specialty retailers. We appreciate the contributions that Neill Davis made to francesca’s and we wish him well in his future endeavors.”

Mr. Barnes said, “I am honored by the Board’s confidence in me and look forward to building francesca’s by leveraging its outstanding brand, unique retailing strategy and deep customer loyalty. I am excited to lead a company with such tremendous potential and look forward to working with the strong leadership team and talented employees at francesca’s.”

francesca’s is announcing preliminary results for its fiscal third quarter ended November 1, 2014. Consistent with the lower end of its guidance, the Company expects net sales of approximately $87 million, a comparable sales decrease of 6%, and diluted earnings per share of $0.17.

As previously announced, francesca’s will report its third quarter results and provide its outlook for the fourth quarter on Wednesday, December 10, 2014, at 7:30 am ET. Mr. Barnes will join the conference call.

About Francesca’s Holdings Corporation:

francesca’s^® is a growing specialty retailer with retail locations designed and merchandised to feel like independently owned, upscale boutiques providing customers a fun and differentiated shopping experience. The merchandise assortment is a diverse and balanced mix of apparel, jewelry, accessories and gifts. Today francesca’s^® operates 538 boutiques in 47 states and the District of Columbia, and serves its customers through francescas.com. For additional information on francesca’s^®, please visit www.francescas.com.

CONTACT: ICR, Inc.
         Jean Fontana
         646-277-1214

         Company
         Mark Vendetti
         832-494-2315
         mark.vendetti@francescas.com

(BIRT) Signs Agreement to be Acquired by OpenText

Actuate Corporation (NASDAQ:BIRT), The BIRT Company™ and the leader in personalized analytics and insights, today announced that it has entered into an agreement to be acquired by OpenText. Under the terms of the merger agreement, an affiliate of OpenText will commence a tender offer to the Actuate stockholders to purchase any and all shares of common stock they hold for $6.60 in cash per share. The purchase price represents an approximately 89% premium to the closing price of Actuate common stock on December 4, 2014, and an equity value of approximately $330 million.

The addition of Actuate enables OpenText to enhance their products with embedded analytics as well as enter a growing market. Together Actuate and OpenText will seek to extend the benefits of embedded analytics to more geographies and industries. Industry research indicates embedded analytics is increasing in its importance. Embedded analytics turns information into intelligence by providing users with relevant, actionable insights delivered within the context of the application. This adds substantial value for companies embedding analytics into applications to help drive better customer engagement and improved decision making.

The Board of Directors of Actuate has unanimously approved the transaction. The transaction is expected to close in the first quarter of 2015, subject to Actuate stockholders tendering a majority of Actuate’s outstanding shares pursuant to the tender offer and other customary closing conditions, including regulatory approvals.

“Actuate has been focused on delivering value of information for over 20 years. We believe this agreement will enhance the OpenText product line through embedded analytics and open a new growth market for OpenText,” said Pete Cittadini, president and CEO of Actuate.

For further information regarding all terms and conditions contained in the definitive merger agreement, please see Actuate’s Current Report on Form 8-K, which will be filed in connection with this transaction.

About Actuate (NASDAQ:BIRT) – The BIRT Company™

Actuate provides software to more than 3.5 million BIRT developers and OEMs who build scalable, secure solutions that save time and improve brand experience by delivering personalized analytics and insights to over 200 million of their customers, partners and employees. Actuate founded and supports BIRT – the open source IDE – and develops BIRT iHub™ – the world-class visualization and deployment platform – to significantly improve productivity of developers working on customer facing applications. Actuate’s BIRT Analytics™ delivers self-service predictive analytics to enhance customer engagement using Big Data. The Actuate Customer Communications Suite™ empowers organizations to easily transform, process, personalize, archive and deliver high volume content and individualized correspondence. Actuate is headquartered in Silicon Valley with more than 5,000 enterprise customers in financial services, technology and government. Visit actuate.com and developer.actuate.com.

Additional Information and Where to Find It

This document does not constitute an offer to buy or a solicitation of an offer to sell securities. The tender offer for the outstanding shares of common stock of Actuate (“Offer”) described in this document has not commenced. At the time the Offer is commenced, OpenText Corporation (“OpenText”) and Asteroid Acquisition Corporation, a wholly‐owned subsidiary of OpenText (the “Merger Subsidiary”) will file a Tender Offer Statement on Schedule TO with the U.S. Securities and Exchange Commission (“SEC”), and Actuate will file a Solicitation/Recommendation Statement on Schedule 14D‐9 with the SEC. The Tender Offer Statement (including an offer to purchase, a related letter of transmittal and other offer documents) and the Solicitation/Recommendation Statement, as they may be amended from time to time, will contain important information that should be read carefully before any decision is made with respect to the Offer. Those materials and all other documents filed by Actuate, OpenText or Merger Subsidiary with the SEC will be available both at no charge on the SEC’s web site at www.sec.gov and may be obtained for free by directing requests to ir@actuate.com.

Cautionary Statement Regarding Forward‐Looking Statements

This document contains forward‐looking statements that involve risks and uncertainties concerning the parties’ ability to close the transaction and the expected closing date of the transaction, and reflect management’s best judgment based on factors currently known. Our actual results may differ materially from those discussed here. These risks and uncertainties include, among others: the timing of the closing of the proposed transaction, the outcome of regulatory reviews of the proposed transaction, the ability of the parties to complete the transaction, the ability of the parties to meet the closing conditions and other risks detailed from time to time in our SEC filings, including our most recent annual report on Form 10‐K and most recent quarterly report on Form 10‐Q. We disclaim any intention or obligation to publicly update or revise any forward‐looking statements, including any guidance, whether as a result of events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Copyright © 2014 Actuate Corporation. All rights reserved. Actuate, legodo, BIRT iHub, BIRT iHub F-Type, BIRT Analytics, Actuate Customer Communications Suite, The Actuate Document Accessibility Appliance, BIRT PowerDocs, BIRT onDemand, BIRT Viewer Toolkit, and the Actuate logo are trademarks or registered trademarks of Actuate Corporation and/or its affiliates in the U.S. and certain other countries. The use of the word “partner” or “partnership” does not imply a legal partnership relationship between Actuate and any other company. All other brands, names or trademarks mentioned may be trademarks of their respective owners.

(OVAS) to Present at the Oppenheimer Healthcare Conference

OvaScience^SM (NASDAQ:OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today that Company management will present at the Oppenheimer 25^th Annual Healthcare Conference on Thursday, December 11, 2014 at 2:10 pm ET at the Crowne Plaza Times Square hotel in New York.

A live audio webcast of the presentation can be accessed by visiting the Investors section of the Company’s website at www.ovascience.com. A replay of the webcast will be archived on the OvaScience website for two weeks following the presentation.

About OvaScience

OvaScience (NASDAQ:OVAS) is a global life sciences company dedicated to improving fertility for women around the world. OvaScience is discovering, developing and commercializing new fertility treatments because we believe women deserve more options. Each OvaScience treatment is based on the Company’s proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPC^SM) cells – immature egg cells found inside the protective ovarian lining. The AUGMENT^SM treatment, a fertility option specifically designed to improve egg health, is available in certain IVF clinics in select international regions outside of the United States. OvaScience is developing the OvaPrime^SM treatment, which could expand a woman’s egg reserve, and the OvaTure^SM treatment, a potential next-generation IVF treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections. For more information, please visit www.ovascience.com and connect with us on Twitter and Facebook.

Forward-Looking Statements

This press release includes forward-looking statements about the Company’s plans for the AUGMENT treatment and its two fertility treatments in development. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: the possibility that international IVF clinics that we work with may determine not to begin or continue providing the AUGMENT treatment for commercial or other reasons; our expectation that the AUGMENT treatment and OvaPrime treatment meet the requirements of a class of products exempt from premarket review and approval under applicable regulations in those countries where we have launched or plan to introduce the AUGMENT treatment and plan to introduce the OvaPrime treatment; the science underlying our treatment and treatments in development (including the AUGMENT, OvaPrime and OvaTure treatments), which is unproven; our ability to obtain regulatory approval where necessary for our potential treatments; our ability to develop our potential treatments, including the OvaPrime and OvaTure treatments, on the timelines we expect, if at all; our ability to commercialize the AUGMENT treatment and our potential treatments, including the OvaPrime treatment, on the timelines we expect, if at all; as well as those risks more fully discussed in the “Risk Factors” section of our most recently filed Quarterly Report on Form 10-Q and/or Annual Report on Form 10-K. The forward-looking statements contained in this press release reflect our current views with respect to future events. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our view as of any date subsequent to the date hereof.

OvaScience:
Cara Petralia, 617-714-9638
Director, Corporate Communications
cpetralia@ovascience.com

(TUBE) Launches PTV, Enabling Programmatic Buying of TV Advertising

The first self-serve software for automated buying of TV ads spans over 80 cable networks and hundreds of local broadcasters, reaching over 90% of American households

NEW YORK, Dec. 4, 2014  — Today, TubeMogul (NASDAQ: TUBE) premiered TubeMogul PTV, a software solution that enables automated, data-driven buying of TV advertising. The product was unveiled at The TimesCenter, with over 250 brands and advertising agencies attending.

Over 10 brands and ad agencies have already signed up for TubeMogul PTV, including 3M, Allstate, Digitas and Levelwing (who will be executing buys on behalf of Gildan USA).

TubeMogul PTV aggregates TV advertising inventory from the major cable and satellite companies, national TV networks and local broadcasters. This is made possible by integrations with the leading TV supply side platforms, including AudienceXpress, clypd and placemedia. At launch, TubeMogul will also be the exclusive buy-side technology partner for WideOrbit, whose WO Programmatic– TV marketplace helps 75% of local TV stations automate their ad sales.

Historically, the planning and buying of TV ads has been a time-consuming, manual process that offered little room for optimization. Targeting is generally limited to age and gender, and navigating the complexities of the upfronts, scatter and disparate regional markets is difficult.

TubeMogul PTV changes that, making every TV ad more valuable and efficient for brand marketers. TubeMogul’s buying software is the first to enable advertisers to target specific TV networks and dayparts. To inform these targets, TubeMogul incorporates data from Nielsen and others, recommending media mixes that index highly toward specific audiences. Targeting is available by: age, gender, income level, ethnicity, educational level, children in household, home ownership status, automobile preferences, pet ownership and more.

As a campaign proceeds, marketers can utilize granular measurement to inform optimization and strategy. Third-party verification and analytics are built into the software, allowing for deeper analysis of shows, dayparts and regions. Instead of adjusting strategy in weeks or months, advertisers can shift spending in real-time based on their goals.

“TubeMogul PTV brings the accountability and control of programmatic buying to TV for the first time,” said Brett Wilson, CEO and Co-Founder of TubeMogul. “By automating TV buys, marketers can focus on strategy and better results for their clients.”

“3M has long been synonymous with innovation and invention, and TubeMogul PTV helps us make sure that our advertising strategy reflects those values,” said Chris Luna, Digital Media Specialist at 3M. “By buying TV through software, we can bring more relevant messages to potential customers.”

“All of our clients need to be able to reach their target audience as media consumption shifts between screens,” said Steve Parker Jr, CEO & Co-Founder at Levelwing. “Today we can use a single piece of software to ensure that we’re improving relevance and resonance among viewers, ultimately improving ROI.”

About TubeMogul
TubeMogul is an enterprise software company for digital branding. By reducing complexity, improving transparency and leveraging real-time data, our platform enables advertisers to gain greater control of their video advertising spend and achieve their brand advertising objectives. TubeMogul was incorporated in 2007 and is based in Emeryville, California with operations in New York, London, Singapore, Tokyo, Sydney, Toronto and offices across the United States.

Press Contact:
David Burch
press@tubemogul.com
1 (510) 653-0501

(CLRB) Granted Orphan Designation for I-131-CLR1404 for the Treatment of Multiple Myeloma

MADISON, Wis., Dec. 4, 2014  — Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, announced that the U.S. Food and Drug Administration (FDA) has granted Cellectar’s request for orphan drug designation of I-131-CLR1404 for the treatment of multiple myeloma, an incurable cancer of plasma cells.

“We are thrilled that I-131-CLR1404 has been designated an orphan drug for the treatment of multiple myeloma,” commented Dr. Natalie Callander, principal investigator of Cellectar’s I-131-CLR1404 multiple myeloma trial, Associate Professor of Medicine, and Director, University of Wisconsin Carbone Cancer Center Myeloma Clinical Program. “Despite advances in the last several decades, multiple myeloma remains an incurable malignancy and agents with new and unique mechanisms of action, such as I-131-CLR1404, are essential to improving outcomes and survival. This designation reflects both the FDA’s and Cellectar’s important focus on addressing the unmet clinical needs of patients with diseases such as multiple myeloma.”

The Orphan Drug Act provides for economic incentives to encourage the development of drugs for diseases affecting fewer than 200,000 people in the United States. Orphan drug designation will entitle Cellectar to seven years of market exclusivity for I-131-CLR1404 as a treatment for relapsed or refractory multiple myeloma following marketing approval by the FDA. Additional benefits include tax credits related to clinical trial expenses, a possible exemption from the FDA-user fee, assistance in clinical trial protocol design, and fewer patients required for new drug applications.

“This orphan designation is a critical milestone in our program and will support our efforts to move I-131-CLR1404 as quickly as possible through the clinical and regulatory development process,” said Dr. Simon Pedder, president and chief executive officer of Cellectar Biosciences. “We are in the final stages of preparing our clinical sites to initiate a proof-of-concept trial of I-131-CLR1404 in multiple myeloma and look forward to working with Dr. Callander to evaluate I-131-CLR1404 as a targeted therapeutic in this indication.”

About Multiple Myeloma

Multiple myeloma is a form of blood cancer that primarily affects older adults and arises from plasma cells in the bone marrow. According to the National Cancer Institute, multiple myeloma is the second most common blood cancer in the United States and constitutes approximately 1 percent of all cancers. The National Cancer Institute estimates that 24,500 Americans will be diagnosed with multiple myeloma in 2014 and 11,090 will die from the disease.

About I-131-CLR1404

I-131-CLR1404 is a small-molecule, broad-spectrum, cancer-targeted radiopharmaceutical comprised of a proprietary optimized phospholipid ether (PLE) analog, acting as a cancer-targeted delivery and retention vehicle, covalently labeled with iodine-131, a cytotoxic radioisotope that is already commonly used to treat thyroid and other cancer types. I-131-CLR1404 is engineered to combine an intracellular radiation mechanism of cancer cell killing with targeted delivery to a wide range of malignant tumor types. Preclinical models have also demonstrated selective uptake and retention in cancer stem cells, suggesting the potential for longer lasting cancer remission.

About Cellectar Biosciences, Inc.

Cellectar Biosciences is developing agents to detect, treat and monitor a broad spectrum of cancers. Using a novel phospholipid ether analog (PLE) platform technology as a targeted delivery and retention vehicle, Cellectar’s compounds are designed to be selectively taken up and retained in cancer cells including cancer stem cells. With the ability to attach both imaging and therapeutic agents to its proprietary delivery platform, Cellectar has developed a portfolio of product candidates engineered to leverage the unique characteristics of cancer cells to “find, treat and follow” malignancies in a highly selective way. I-124-CLR1404 is a small-molecule, broad-spectrum, cancer-targeted PET imaging agent currently being evaluated in a Phase II glioblastoma imaging trial. Additionally, multiple investigator-sponsored Phase I/II clinical trials are ongoing across 11 solid tumor indications. I-131-CLR1404 is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells including cancer stem cells. A Phase Ib dose-escalation trial of I-131-CLR1404 in patients with advanced solid tumors was completed in the first quarter of 2014 and results presented at the American Society of Clinical Oncology (ASCO) 2014 Annual Meeting. CLR1502 is a preclinical, cancer-targeted, non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging. For additional information please visit www.cellectar.com

This news release contains forward-looking statements. You can identify these statements by our use of words such as “may,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate,” “continue,” “plans,” or their negatives or cognates. These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our pharmaceutical collaborators’ ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended December 31, 2013. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to update any such forward-looking statements.

CONTACT: INVESTOR CONTACT

         Kate McNeil, Vice President of IR, PR & Corporate Communications
         Cellectar Biosciences, Inc.
         Phone: (347) 204-4226
         Email: kmcneil@cellectar.com

(TLOG) Clinical Data on Birinapant To Debut At 56th Annual American Society of Hematology

MALVERN, Pa., Dec. 4, 2014  — TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced that two abstracts related to clinical data on birinapant will be presented at the 56^th Annual American Society of Hematology meeting to be held in San Francisco from December 6-9, 2014.

The date and time of the poster presentations are as follows:

About TetraLogic Pharmaceuticals Corporation

TetraLogic is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases. TetraLogic has two clinical-stage product candidates in development: birinapant and SHAPE. Birinapant is currently being tested in Phase 1 and Phase 2 clinical trials for hematological malignancies and solid tumors, and is also being tested in a Phase 1b/2a clinical trial in hepatitis B. SHAPE is entering a Phase 2 clinical trial for early-stage Cutaneous T-cell Lymphoma.

Forward Looking Statements

Some of the statements in this release are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements relate to future events or TetraLogic’s pre-clinical and clinical development of birinapant, SHAPE and other clinical programs, future expectations, plans and prospects. Although TetraLogic believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. TetraLogic has attempted to identify forward looking statements by terminology including ”believes,” ”estimates,” ”anticipates,” ”expects,” ”plans,” ”projects,” ”intends,” ”potential,” ”may,” ”could,” ”might,” ”will,” ”should,” ”approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under the heading “Risk Factors” in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 19, 2014 and in our form 10-Q filed with the SEC on November 5, 2014. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

CONTACT: Company Contact:
         Pete A. Meyers
         Chief Financial Officer and Treasurer
         TetraLogic Pharmaceuticals Corporation
         (610) 889-9900, x103
         pete.meyers@tlog.com

         Investor Relations Contact:
         Ami Bavishi
         Burns McClellan, Inc.
         (212) 213-0006
         abavishi@burnsmc.com

(ALSK) GCI to Purchase Wireless Subscriber Base from Alaska Communications

Alaska Communications System Group, Inc. (NASDAQ:ALSK) and General Communication, Inc. (GCI) (NASDAQ:GNCMA) have signed definitive agreements for Alaska Communications to sell its wireless subscriber base and its 33 percent interest in its partnership in the Alaska Wireless Network, LLC (AWN) to GCI for $300 million.

Under the terms of the agreements and upon close:

• GCI will assume Alaska Communications’ wireless subscriber base. Services will be uninterrupted and will continue to operate statewide and nationally.
  • As of September 30, 2014, Alaska Communications had approximately 109,000 wireless customers.
• GCI will purchase Alaska Communications’ 33 percent interest in AWN and will then own 100 percent of AWN. Upon close, these agreements will eliminate future preferred and partnership distributions that otherwise would have been due under the original AWN agreements. Up until close Alaska Communications will continue to receive preferred distributions from AWN.
• The two companies have agreed upon a service transition plan for Alaska Communications customers. This will ensure a seamless continuation of service as they are transitioned to GCI.
• Alaska Communications wireless customers will continue to enjoy service on Alaska’s only statewide network.
• The transaction is targeted to close in the first quarter, 2015, and is subject to certain closing conditions.

“We are pleased to reach these agreements that allow each company to pursue its own strategy,” said Alaska Communications President and CEO Anand Vadapalli and GCI President and CEO Ron Duncan in a joint statement. “We are committed to a seamless service transition for wireless customers. Alaskans will continue to benefit from a vibrant competitive market for wireless services.”

Vadapalli added, “We appreciate the loyal support of our wireless customers and thank our wireless team who consistently deliver excellent customer service. We will continue to provide customers with this same level of quality service and support during the transition of wireless services.”

Duncan concluded, “We welcome wireless subscribers from Alaska Communications and are committed to providing them the latest technologies and superior customer service on Alaska’s only statewide network.”

GCI and Alaska Communications will notify customers with further details regarding this transition and customers do not need to take any action at this time.

About the Alaska Wireless Network (AWN)

AWN was formed in July 2013 and combined the wireless network assets of Alaska Communications and GCI. The transaction was designed to position the two companies to better compete against national wireless carriers. Under terms of the agreement, GCI retained two-thirds ownership and Alaska Communications retained one-third ownership.

About Alaska Communications

Alaska Communications (NASDAQ: ALSK) is a leading provider of advanced broadband and managed service solutions for businesses and consumers in Alaska. The Company operates a highly reliable, advanced statewide data and voice network with the latest technology and the most diverse undersea fiber optic system connecting Alaska to the contiguous United States. For more information, visit www.alaskacommunications.com or www.alsk.com.

About GCI

GCI is the largest Alaska-based and -operated, integrated telecommunications provider, offering wireless, voice, data, and video services statewide. Learn more about GCI at www.gci.com.

Forward-Looking Statements

This joint release includes certain “forward-looking statements,” as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s beliefs as well as on a number of assumptions concerning future events made using information currently available to management. Readers are cautioned not to put undue reliance on such forward-looking statements, which are not a guarantee of performance and are subject to a number of uncertainties and other factors, many of which are outside GCI’s or Alaska Communications’ control. For further information regarding risks and uncertainties associated with either company’s business, please refer to either GCI’s or Alaska Communications’ SEC filings.

(RADA) Leading MOD Selects RADA’s Tactical Radars for Its National Alert System

RADA’s Tactical Radar Systems Provide Volume Surveillance and Detection of Multiple Threat Types, Including UAVs, Mortars, and Rockets

NETANYA, Israel, Dec. 4, 2014  — RADA Electronic Industries Ltd. (Nasdaq:RADA) announces the selection of its MHR-based tactical radars by a leading MOD of for its national alert system. The radars will detect and alert from short-range threats such as mortars, rockets, UAVs and alike.

Deliveries are expected to be completed during 2015.

The MHR – an S-Band, Software-Defined, Pulse-Doppler, AESA radar – has sophisticated beam forming capabilities and advanced signal processing, provides multiple missions on each radar platform, and offers unprecedented performance-to-price ratio. It is compact and mobile, delivering ideal organic, tactical surveillance solutions for force and border protection applications such as C-UAS, C-RAM, GMTI, air surveillance, and more.

According to Zvi Alon, RADA’s CEO, “We are extremely proud with this competitive selection of our technology. This is a major award of a radar program for RADA, which joins other strategic awards for radar programs during 2014. We believe that additional leading countries and integrators will follow this selection.”

About RADA

RADA Electronic Industries Ltd. is an Israel-based defense electronics contractor. The Company specializes in the development, production, and sale of Tactical Land Radars for Force and Border Protection, Inertial Navigation Systems for air and land applications, and Avionics Systems and Upgrades.

CONTACT: RADA
         Dubi Sella (CBDO)
         Tel: +972-9-892-1111
         mrkt@rada.com
         www.rada.com

(OTIV) Announces Pricing of Public Offering of Ordinary Shares

(MPET) Announces Potential Acquisition of CO2 Source and Poplar Pilot Update

(ORMP) Closes $5 Million Investment From Guangxi Wuzhou Pharmaceutical Company

JERUSALEM, Israel, December 3, 2014 —

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP), a developer of oral drug delivery systems, today announced that it has received $5 million in connection with the definitive agreement with Guangxi Wuzhou Pharmaceutical Co., Ltd., a subsidiary of Guangxi Wuzhou Zhongheng Group Company Ltd (SHA:600252) previously reported on November 3, 2014, for the purchase of 696,378 restricted shares of common stock for $7.18 per share, the closing price of Oramed’s common stock on Friday, October 31, 2014, in a private placement.

Guangxi Wuzhou Zhongheng Group Company Ltd is an investment holding company publicly traded on the Shanghai Stock Exchange.

“We are pleased to have Wuzhou as a new shareholder,” noted Nadav Kidron, Chief Executive Officer of Oramed. “China offers a substantial market opportunity for our diabetes focused pipeline and we are delighted to have Wuzhou as a supportive shareholder, as they can help strategically guide our development and commercial entrance into China,” commented CEO Nadav Kidron.

Oramed intends to use the net proceeds from this offering for expenses primarily related to the Company’s anticipated U.S. focused clinical development programs for its oral insulin for type 1 and type 2 diabetes indications, for preclinical and clinical studies of its oral GLP-1 analog project, and for general corporate purposes, including general working capital purposes.

This press release is neither an offer to sell nor a solicitation of an offer to buy any of the Company’s securities. No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed’s Protein Oral Delivery (POD™) technology is based on over 30 years of research by top scientists at Jerusalem’s Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). Having completed separate Phase IIa clinical trials, the company anticipates the initiation of separate Phase IIb clinical trials, in patients with both type 1 and type 2 diabetes under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition the company is developing an oral GLP-1 analog capsule (ORMD-0901).

For more information, the content of which is not part of this press release, please visit  http://www.oramed.com

Forward-looking statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, we are using forward-looking statements when we discuss our clinical trials, including the expected timing thereof, and revolutionizing the treatment of diabetes with our products. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed’s reports filed from time to time with the Securities and Exchange Commission.

Company Contact
Oramed Pharmaceuticals
Ariella Nachman
Office: +972-2-566-0001 ext. 2
US: +1-718-831-2512 ext. 2
Email: ariella@oramed.com

(ALCO) Announces Three Strategic Acquisitions

Combined Entity Will Be the Largest Citrus Producer in the U.S.

FORT MYERS, Fla., Dec. 3, 2014  — Alico, Inc. (NASDAQ: ALCO, “Alico” or “the company”), an agriculture and natural resources company, today announced the acquisition of three Florida citrus producers for total consideration of approximately $363 million. These acquisitions will make Alico’s citrus division the largest citrus producer in the United States, with total pro forma 2014 production of 10 million boxes annually.

The acquisitions, based on 2014 performance, would have increased Alico’s Adjusted EBITDA from $21 million on a standalone basis to approximately $58 million on a pro forma basis, excluding the impact of anticipated synergies, which, when fully phased in, are expected to add approximately $5 million of incremental EBITDA annually. Similarly, the transactions would have increased Alico’s 2014 Adjusted Earnings per Share and Adjusted Free Cash Flow per Share from $1.00 and $0.96 on a standalone basis to approximately $2.77 and $3.31, respectively, on a pro forma basis, excluding anticipated synergies and one-time items.

“These transactions are transformative for our citrus business and represent a major step forward in our strategy to become a leading agriculture and natural resources company by identifying and executing on accretive growth opportunities,” said Clay Wilson, Chief Executive Officer of Alico. “We intend to continue to target attractive markets and establish leading positions in our different business lines where scale and expertise can generate strong returns for our investors.”

“With the support of our Board of Directors, we have taken these actions to meaningfully enhance our position in the citrus industry. We have done this by maintaining our focus on the return characteristics of each of our assets and, where appropriate, redeploying capital to seek higher returns,” said Hank Slack, Chairman of Alico’s Board of Directors. “We believe that what we have done in the citrus space can be replicated across our other business lines to further strengthen and grow the Alico franchise.”

The three acquisitions are: (1) certain assets and liabilities of Orange-Co, LP, (2) 734 Citrus Holdings, LLC, also known as Silver Nip Citrus, and (3) Gator Grove.

The Orange-Co assets include approximately 20,263 acres, which comprises one of the largest contiguous citrus grove properties in the state of Florida. The $274 million Orange-Co acquisition was financed with proceeds from Alico’s recently announced $97 million sale of its sugarcane assets and a portion of the proceeds from Alico’s new long-term debt facilities and related credit lines. The Orange-Co acquisition closed on December 2, 2014.

Silver Nip Citrus is comprised of approximately 7,434 acres. The $72 million Silver Nip Citrus acquisition will be financed with the rollover of its existing credit facilities totaling $43 million and the issuance of approximately 0.8 million shares of Alico common stock. The Silver Nip Citrus acquisition is expected to close in the first quarter of 2015. The closing of the Silver Nip Citrus acquisition is subject to the satisfaction and waiver of other customary conditions. 734 Investors, LLC, Alico’s majority shareholder, will seek the consent of a majority of its disinterested members to direct 734 Investors to approve the issuance of Alico common stock in the acquisition by written consent of its Alico shares. In connection with the Silver Nip Citrus acquisition, the company anticipates issuing additional shares of Alico common stock to the sellers at the end of the 2014/2015 citrus harvest season based on the net proceeds received from the sale of citrus fruit harvested on certain Silver Nip Citrus groves.

Gator Grove is comprised of approximately 1,241 acres contiguous to the Orange-Co property. The $16.6 million Gator Grove acquisition was financed with cash on hand and closed on September 23, 2014.

Pro forma for the closing of the transactions, net debt is expected to be approximately $232 million with a weighted average cost of 3.6 percent (based on current interest rates), and the company will have approximately 8.2 million fully diluted shares outstanding.

Transaction Highlights

Management believes that the acquisitions will yield significant benefits for the company and its shareholders, including:

Creates the largest citrus producer in the U.S. Pro forma for the transactions announced today, Alico’s citrus division will be the largest citrus producer in the U.S. The acquisitions increase the citrus division’s total net grove acres from approximately 10,900 acres on a standalone basis to approximately 32,600 acres on a pro forma basis (+199 percent increase), and increase total box production for the last twelve months ending September 30, 2014 from approximately 3.4 million boxes on a standalone basis to approximately 10.0 million boxes on a pro forma basis (+189 percent increase).

Significant increase in EBITDA and free cash flow. The acquisitions are expected to drive significant increases in Alico’s earnings and free cash flow. Pro forma for the acquisitions and anticipated synergies, Alico would have generated 2014 Adjusted EBITDA of approximately $63 million. Pro forma capital expenditures are estimated to be approximately $7.5 million annually, excluding growth initiatives and one-time items. Pro forma interest expense is estimated to be approximately $9 million annually. The acquisitions provide for the company to retain the earnings and cash flow from Orange-Co’s and Gator Grove’s 2014/2015 harvest, which is expected to be completed by June 2015. The sale of the company’s sugarcane assets and the subsequent reinvestment of the sale proceeds into the Orange-Co assets were structured as a 1031 like-kind exchange, deferring the recognition of any taxable gain on the recently announced sale. In addition, the tax attributes of the acquired assets are expected to substantially reduce taxable income for the 2015 fiscal year.

Highly attractive, long-term financing package. The company secured attractive long-term financing to fund the acquisitions and refinance existing indebtedness. The company’s new debt facilities are comprised of $182.5 million of fixed-rate and floating-rate funded term loans with a 15-year term and a weighted average cost of 3.5 percent (based on current interest rates), as well as a $70 million working capital facility and a $25 million revolving line of credit. Pro forma for the acquisitions, anticipated synergies and the related financing transactions, the company’s net debt-to-EBITDA will be approximately 3.7x and EBITDA-to-interest expense will be approximately 6.9x. After taking effect for these transactions, the company will have approximately $70 million of available liquidity.

Positions the company for long-term growth. The company is capitalized in a manner that management believes can support additional growth through the investment of free cash flow and additional balance sheet capacity. Management expects to continue to actively evaluate the company’s portfolio, maximize cash flow from existing assets, redeploy capital as appropriate, and establish leading positions in each of its core business lines.

Raymond James acted as financial advisor and provided a fairness opinion to the company with respect to the Orange-Co acquisition. Wachtell, Lipton, Rosen & Katz acted as legal counsel to the company with respect to the Orange-Co and Silver Nip Citrus acquisitions. Houlihan Lokey provided a fairness opinion to a special committee of disinterested members of the Board of Directors of Alico in connection with the Silver Nip Citrus acquisition.

Use of Non-GAAP Financial Measures

This press release discloses certain financial measures that are considered non-GAAP financial measures. Generally, a non-GAAP financial measure is a numerical measure of a company’s financial performance, financial position or cash flows that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. The company uses both Generally Accepted Accounting Principles (GAAP), and non-GAAP or adjusted financial measures, to evaluate and report the results of its business. A reconciliation of the non-GAAP financial measures to the comparable GAAP financial measure is available on the company’s home page at www.alicoinc.com at http://ir.stockpr.com/alicoinc/shareholder-information. As used herein, “GAAP” refers to the accounting principles generally accepted in the United States.

About Alico, Inc.

Alico is a holding company with assets and related operations in agriculture and natural resources. In addition to its citrus operations, Alico is currently involved in cattle ranching, water management, mining and other natural resources, including approximately 122,000 acres of agricultural assets (pro forma for the acquisitions) and 90,000 acres of mineral rights. In November 2013, 734 Investors, LLC acquired a controlling 51 percent stake in Alico. Subsequent to this investment, the company has executed on a strategy of optimizing assets and capital allocation. The company expects to continue this strategy by using its free cash flow and balance sheet capacity to execute additional acquisitions, where management believes it can add value and generate attractive returns for Alico’s shareholders.

Forward-Looking Statements

We provide forward-looking information in this release pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Any statements in this release that are not historical facts are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on our current expectations, estimates and projections about our business based, in part, on assumptions made by our management. These assumptions are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including those risk factors described in our Annual Report on Form 10-K for the year ended September 30, 2013 and our Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (“SEC”).

Additional Information About the Proposed Silver Nip Citrus Acquisition and Where to Find It

Investors and security holders are urged to carefully review and consider Alico’s public filings with the SEC, which may be obtained free of charge at Alico Inc.’s website at www.alicoinc.com or at the SEC’s website at www.sec.gov. These documents may also be obtained free of charge from Alico by requesting them in writing to Alico Inc., 10070 Daniels Interstate Court, Suite 100, Fort Myers, FL 33913, Attention: Investor Relations, or by telephone at (239) 226-2000.

In connection with the proposed acquisition of Silver Nip Citrus, Alico will file with the SEC an information statement of Alico and certain other documents regarding the proposed acquisition. Investors and security holders of Alico are urged to carefully read the entire information statement, when it becomes available, because it will contain important information about the proposed acquisition. Information about the directors and executive officers of Alico and their ownership of Alico common stock is set forth in the definitive proxy statement for Alico’s 2014 annual meeting of shareholders, as previously filed with the SEC on January 24, 2014.

(SQNM) & Illumina Noninvasive Prenatal Testing IP, End Outstanding Patent Disputes

Illumina, Inc. (NASDAQ: ILMN) and Sequenom, Inc. (NASDAQ: SQNM) today announced they have agreed to settle all pending infringement claims and other disputes between Sequenom and Verinata Health, Inc. The parties will pool their owned and in-licensed intellectual property directed to noninvasive prenatal testing (NIPT), including patents that will remain the subject of ongoing interference proceedings.

Under the agreement, Illumina will have exclusive worldwide rights to utilize the pooled intellectual property to develop and sell in-vitro diagnostic kits for NIPT and to license third-party laboratories wishing to develop and sell their own laboratory-developed NIPT tests under the collection of pooled patents. In addition, Sequenom and Illumina will each have rights to utilize all pooled patents to develop and sell their own respective laboratory-developed NIPT tests. The parties will share the revenue from the patent pool and Illumina will pay Sequenom a royalty on sales of in-vitro diagnostic kits for NIPT.

Illumina will make a $50 million upfront payment to Sequenom as part of the overall agreement, as well as certain ongoing commitments for payments to Sequenom from the patent pool structure through 2020.

“The patent pool established through this agreement eliminates confusion over intellectual property rights and provides a single point of contact for those wishing to license this intellectual property for NIPT testing,” said Jay Flatley, Chief Executive Officer for Illumina.

“This settlement will allow for easier access to both parties’ NIPT technology by healthcare providers and their patients,” said Bill Welch, Chief Executive Officer of Sequenom. “We believe that pooling our intellectual property will enable us to continue to expand our NIPT laboratory test offerings while allowing Sequenom to participate more broadly in the growing global NIPT marketplace.”

Separately, Illumina and Sequenom entered into an amended supply agreement whereby Illumina agreed to supply Sequenom with instruments and reagents for an additional five years.

“Sequenom and Illumina will now be able to utilize all of their pioneering intellectual property in the NIPT testing field in order to enable and deliver the highest quality NIPT tests to benefit physicians and their patients,” said Tristan Orpin, Senior Vice President and General Manager of Reproductive and Genetic Health for Illumina.

About Illumina

Illumina is transforming human health as the global leader in sequencing and array-based technologies. The company serves customers in a broad range of markets, enabling the adoption of genomic solutions in research and clinical settings. To learn how Illumina is unlocking the power of the genome, visit www.illumina.com and follow @illumina.

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving health care through revolutionary genomic and genetic analysis solutions. Sequenom develops innovative technologies, products, and diagnostic tests that target and serve molecular diagnostic markets. Web site: www.sequenom.com and follow @SQNM.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20141203005307/en/

(ARRY) To Regain Worldwide Rights To Binimetinib

– Array to receive up to $85 million upfront payment from Novartis – – Novartis to conduct and/or substantially fund all ongoing and several planned clinical studies, including COLUMBUS, NEMO and MILO – – Agreement subject to Novartis-GSK transaction close – – Conference call to discuss transaction on Thursday, December 4, 2014 at 9:00 a.m. Eastern Time –

BOULDER, Colo., Dec. 3, 2014  — Array BioPharma Inc. (NASDAQ: ARRY) today announced that it has reached a definitive agreement with Novartis International Pharmaceutical Ltd. to regain full worldwide rights to binimetinib, a MEK inhibitor in three Phase 3 trials.  This agreement is conditional on the closing of transactions announced by Novartis and GlaxoSmithKline PLC (GSK) on April 22, 2014, which are expected in the first half of 2015, and remain subject to regulatory approval. Array had previously granted Novartis worldwide exclusive rights to develop and commercialize binimetinib under a 2010 License Agreement, which will terminate and be superseded by a new set of agreements between the parties.

“Regaining full worldwide rights to binimetinib, an innovative late-stage oncology product, represents a tremendous opportunity for Array,” said Ron Squarer, Chief Executive Officer, Array BioPharma.  “Binimetinib is currently advancing in three Phase 3 clinical trials and, we expect to file for our first regulatory approval during the first half of 2016.  With this agreement, we are in a strong position to successfully develop and commercialize binimetinib to the benefit of cancer patients.”

Novartis stated, “Binimetinib has demonstrated promising results for cancer patients across several different clinical trials.  We are committed to supporting a successful transition to Array.”

Terms of the Agreement
Upon deal close, Array will receive up to $85 million and Novartis’ global, exclusive license to binimetinib will terminate with all rights reverting to Array.  Novartis has agreed to provide transitional regulatory, clinical development and manufacturing services as specified below and will assign to Array patent and other intellectual property rights it owns to the extent relating to binimetinib.  All clinical trials involving binimetinib, including the COLUMBUS, NEMO and MILO pivotal trials, will continue to be conducted as currently contemplated.

Novartis will be responsible for continued conduct and funding of the COLUMBUS trial.  This obligation will transfer to any future owner of LGX818 (encorafenib).  Following deal close, Novartis will reimburse Array for all remaining out-of-pocket expenses and half of all remaining fully-burdened full time equivalent (FTE) costs associated with MILO, which Array will continue to conduct.  For NEMO and all other ongoing and planned clinical trials, Novartis will conduct and solely fund each trial, until a mutually agreed-upon transition date to Array.  Following this transition, Novartis will reimburse Array for all remaining out-of-pocket expenses and half of all remaining fully-burdened FTE costs required to complete these studies.

Novartis will remain responsible for conducting and funding development of the NRAS melanoma companion diagnostic until Premarket Approval is received from the U.S. Food and Drug Administration.  Following approval, Novartis will transfer the product and Premarket Approval to a diagnostic vendor of Array’s designation.

Novartis also retains binimetinib supply obligations for all clinical and commercial needs for up to 30 months after closing and will also assist Array in the technology and manufacturing transfer of binimetinib.  Novartis will also provide Array continued access to several Novartis pipeline compounds including, but not limited to, LEE011 (CDK 4/6 inhibitor) and BYL719 (α-PI3K inhibitor), for use in currently ongoing combination studies, and possible future studies, including Phase 3 trials, with binimetinib.

Conference Call Information
Array will hold a conference call on Thursday, December 4, 2014 at 9:00 a.m. Eastern Time to discuss this announcement.  Ron Squarer, Chief Executive Officer, will lead the call.

About MEK and Binimetinib
MEK is a key protein kinase in the RAS/RAF/MEK/ERK pathway, which regulates several key cellular activities including proliferation, differentiation, migration, survival and angiogenesis. Inappropriate activation of this pathway has been shown to occur in many cancers, in particular through mutations in BRAF, KRAS and NRAS.  Binimetinib is a small-molecule MEK inhibitor that targets a key enzyme in this pathway.  Three Phase 3 trials with binimetinib in advanced cancer patients continue to enroll: NRAS-mutant melanoma (NEMO), low-grade serous ovarian cancer (MILO) and BRAF-mutant melanoma (COLUMBUS).  NRAS-mutant melanoma represents the first potential indication for binimetinib, with a projected regulatory filing estimated in the first half of 2016.

About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.  Six Phase 3 studies on Array invented drugs, binimetinib (partnered with Novartis) and selumetinib (partnered with AstraZeneca), are currently enrolling patients with cancer. For more information on Array, please go to www.arraybiopharma.com.

Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the closing of the transaction with Novartis, the timing of the completion or initiation of further development of binimetinib, expectations that the return of rights to binimetinib to Array and other events will occur that will result in greater value for Array, the potential for the results of ongoing preclinical and clinical trials to support regulatory approval or the marketing success of a drug candidate, future plans to progress and develop binimetinib, and our plans to build a commercial-stage biopharmaceutical company. These statements involve significant risks and uncertainties, including those discussed in our most recent annual report filed on Form 10-K, in our quarterly reports filed on Form 10-Q, and in other reports filed by Array with the Securities and Exchange Commission. Because these statements reflect our current expectations concerning future events, our actual results could differ materially from those anticipated in these forward-looking statements as a result of many factors. These factors include, but are not limited to, our ability to continue to fund and successfully progress our proprietary drugs; our ability to effectively and timely conduct clinical trials in light of increasing costs and difficulties in locating appropriate trial sites and in enrolling patients who meet the criteria for certain clinical trials; risks associated with our dependence on third-party service providers to successfully conduct clinical trials within and outside the United States; our ability to achieve and maintain profitability and maintain sufficient cash resources; and our ability to attract and retain experienced scientists and management. We are providing this information as of December 3, 2014. We undertake no duty to update any forward-looking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such statements.

(ENPH) Selects Enphase Energy as Preferred Inverter Supplier

Enphase Energy, Inc. (NASDAQ:ENPH) announced today that the company has been selected as the preferred inverter supplier for Revolve Solar via its distribution arrangement with wholesale distributor CED Greentech. Revolve Solar is a rapidly growing full-service residential and commercial solar company, with operations in Redding, Chico and Vacaville, California, as well as its home office in Austin, Texas.

“We’ve been very successful with our consultative sales approach that emphasizes customer education, high-quality products and attractive financing options,” said Rick Davis, EVP of business development at Revolve Solar. “We spend time with our customers to help them understand that the Enphase system will significantly enhance the long-term return on their solar investment.”

“We’ve been selling Enphase products for many years and consider them a great channel partner who shares our commitment to integrity and reliability,” said Greg Bennett, manager of CED Greentech’s San Leandro, Calif., office. “As one of our fastest-growing customers, Revolve Solar appreciates CED’s proven ability to deliver system components on a timely basis so they can focus on sales and customer service rather than managing inventory.”

“Revolve is well known for its seasoned and highly disciplined sales organization focused on quality and customer service,” said Jeff Loebbaka, senior vice president of global sales, marketing and support at Enphase Energy. “Enphase systems offer the best solar solution for Revolve customers based on our superior performance, highest energy production, and ease of design and installation. As the preferred inverter provider for Revolve Solar, we are continuing our ongoing efforts to strengthen and grow our channel partnerships.”

About Revolve Solar

Founded in Austin, Texas, in 2012, Revolve Solar makes going solar easy and affordable. We help interested, qualifying candidates take the next step in energy evolution by utilizing local and federal incentives to install solar PV on the rooftops of their homes and small businesses. More PV in our communities means lower utility bills, stronger electrical grids and a cleaner environment. Since what goes around comes around, we trust that clean energy is just good, common sense. To us, a secure energy future means placing more energy choices in the hands of people—homeowners and business owners who see the value in reducing their dependency on polluting energy sources and enjoying the multitude of benefits that go along with utilizing true renewable energy sources. We hire installers locally to build the local solar community from our locations in California and Texas. RevolveSolar.com

About CED Greentech

CED Greentech is a division of Consolidated Electrical Distributors Inc., one of the largest electrical product wholesale distributors in the country. As a full-service wholesale distributor of solar, electrical and renewable energy products with 18 locations in the U.S., we are committed to providing superior service and support. We have an extensive onsite inventory featuring products from the solar and electrical industry’s top manufacturers. Whether your project is residential or commercial, we’re confident we’ll have what you need when you need it. www.cedgreentechus.com

About Enphase Energy, Inc.

Enphase Energy delivers microinverter technology for the solar industry that increases energy production, simplifies design and installation, improves system uptime and reliability, reduces fire safety risk and provides a platform for intelligent energy management. Our semiconductor-based microinverter system converts energy at the individual solar module level and brings a systems-based, high technology approach to solar energy generation. Connect with Enphase on Facebook and follow us on Twitter. www.enphase.com

Enphase Energy®, the Enphase logo and other trademarks or service names are the trademarks of Enphase Energy, Inc.

(VGGL) & HGTV Collaborate to Amplify TV Viewing Experience

Viggle Inc. (NASDAQ:VGGL), the entertainment marketing and rewards platform, today announced a strategic marketing partnership with HGTV. The partnership will create a cross-marketing platform to increase audience adoption and enhance HGTV viewers’ experience by providing them with exclusive points and rewards for engaging with HGTV programming across the Viggle Inc. platform, including the free Viggle app, Wetpaint.com and Viggle Reminders.

Fans who check-in to HGTV shows while using the Viggle app will receive bonus points and top-earning fans will be rewarded with HGTV prizes. The partnership includes the following key components:

• Loyalty & Engagement: Viewers will earn 4X points for checking into any primetime HGTV programs from 8PM – 11PM ET/PT with the Viggle app, available on iOS, Android and Windows. Viggle will also produce play-along experiences for key HGTV programs to keep users engaged while tuned-in. Wetpaint will create custom articles and videos so fans can engage with HGTV before and after the shows.
• Rewards: Fans who check-in the most to HGTV programs will earn top fan status and receive exclusive HGTV prizes and rewards from Viggle.
• Tune-In Reminder & Social Tools: HGTV will have access to Viggle’s suite of Publisher Tools, including one click Reminders and Set DVR functionality across all its marketing channels, the ability to add Viggle Point earning capabilities across its own channels, and the use of Viggle Inc.’s proprietary Social Distribution technology.
• Marketing: HGTV and Viggle will co-promote the special benefits on Viggle, as well as HGTV priority programming.
• Data: HGTV will leverage check-in data to gain insights around viewing behavior and engagement.

“We’re thrilled to partner with one of the leading cable networks to offer engaging experiences and rewards for their top viewers,” said Greg Consiglio, president and COO of Viggle Inc. “We are constantly seeking innovative ways to make the TV experience more engaging and rewarding and this partnership exemplifies those goals on several levels. HGTV’s content is perfectly aligned for us to create unique promotions across the Viggle platform and our newly announced publisher tools will help fans of these shows to never miss an episode.”

The 15-month partnership kicks off in December, with Viggle providing the network a platform for reaching and engaging their target audience through their mobile devices while watching TV.

“By engaging with our targeted audience across multiple platforms, we are able to obtain key insights about our viewers beyond demographics,” said Shannon Driver, SVP of Marketing and Creative at Scripps Interactive. “The Viggle platform offers innovative loyalty solutions with targeting, reaching our core audience on their mobile devices while they watch TV, and we are excited to be able to offer this opportunity to our viewers.”

About Viggle Inc.

Viggle is an entertainment marketing and rewards platform whose app rewards its members for watching TV shows and discovering new music. Viggle Platform had total reach of 26.2 million in September 2014, including over 7 million Viggle registered users. Since its launch, Viggle members have redeemed over $20 million in rewards for watching their favorite TV programs and listening to music. Members can use Viggle’s store, accessible through the Viggle app or on Viggle.com, to redeem their Viggle Points for TV show, movie, and music downloads. In addition, Viggle operates Wetpaint, which offers entertainment and celebrity news online; NextGuide, maker of technology that helps consumers search for, find, and set reminders for TV shows and movies; and Choose Digital, a digital marketplace platform that allows companies to incorporate digital content into existing rewards and loyalty programs in support of marketing and sales initiatives. For more information, visit www.viggle.com or follow us on Twitter @Viggle.

About HGTV

America’s leading home and lifestyle brand, HGTV features a top-rated cable network that is distributed to more than 96 million U.S. households and HGTV.com, the premier source for home-related inspiration, instruction and entertainment, attracts more than six million people each month. The brand also includes the HGTV HOME™ consumer products line which showcases exclusive collections of paint, flooring, lighting, furniture, plants, fabrics and other home-oriented products. For more information on HGTV HOME branded products and to find a retailer, go to www.hgtvhome.com. In partnership with Hearst Magazines, the HGTV Magazine, a home and lifestyle publication, is currently available on newsstands. Viewers can become fans of HGTV and interact with other home improvement enthusiasts through Facebook, Twitter, Pinterest and Instagram. Headquartered in Knoxville, Tenn., HGTV is wholly owned by Scripps Networks Interactive, Inc. (SNI).

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. All information provided in this press release is as of the date of this release. Except as required by law, Viggle Inc. undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.

(REI) Continues 2014 Development Program

Company Operates Profitably at Current Commodity Prices

Ring Energy, Inc. (NYSE MKT: REI) (“Ring” or the “Company”) today reaffirmed their 2014 development program and capital expenditure budget of $125 million. Management felt it necessary to reconfirm their stated 2014 development program because of the recent decline in commodity prices.

Through the first three quarters of 2014, the Company had drilled 92 new development wells on its Texas properties and is on pace to drill approximately 135 by year end. The Company continues to add acreage to its core Texas properties, as well as reduce the overall drilling and development costs. At the end of the year, management will evaluate the results and determine the 2015 expenditure budget.

As is the Company’s policy, a 2014 fourth quarter/year-end operations update will be released in early January 2015.

Mr. Kelly Hoffman, Ring CEO, stated, “We continue to execute our development plan and add acreage to our core properties. Our operations personnel are working hard to cut costs wherever possible. Because of the recent drop in commodity prices we will continue to monitor our expenditures closely. However, we currently have a strong balance sheet, unused credit facility and can continue to operate profitably at $60 oil.”

About Ring Energy, Inc.

Ring Energy, Inc. is an oil and gas exploration, development and production company with current operations in Texas and Kansas. www.ringenergy.com

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995 that involve a wide variety of risks and uncertainties, including, without limitations, statements with respect to the Company’s strategy and prospects. Such statements are subject to certain risks and uncertainties which are disclosed in the Company’s reports filed with the SEC, including its Form 10-K for the fiscal year ended December 31, 2013, its Form 10-Q for the quarter ended September 30, 2014 and its other filings with the SEC. Readers and investors are cautioned that the Company’s actual results may differ materially from those described in the forward-looking statements due to a number of factors, including, but not limited to, the Company’s ability to acquire productive oil and/or gas properties or to successfully drill and complete oil and/or gas wells on such properties, general economic conditions both domestically and abroad, and the conduct of business by the Company, and other factors that may be more fully described in additional documents set forth by the Company.

(IDRA) Cancer Immunotherapy Regimen With Intratumoral IMO-2055

Data Highlight Potential Opportunity to Enhance Activity of Emerging Class of Checkpoint Inhibitors With Idera’s Proprietary Toll-Like Receptor Agonists

CAMBRIDGE, Mass., Dec. 2, 2014  — Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing nucleic acid therapeutics for patients with cancer and rare diseases, today announced new preclinical data that showed cancer immunotherapy with intratumoral injections of IMO-2055 and ipilimumab demonstrated potent and systemic anti-tumor activity in multiple preclinical cancer models. IMO-2055 is a synthetic oligonucleotide-based agonist of Toll-like receptor (TLR) 9 discovered and developed by Idera. Ipilimumab is a checkpoint inhibitor targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). The data were presented at the American Association for Cancer Research (AACR) Tumor Immunology and Immunotherapy Meeting in Orlando, Fla., earlier today.

In the presentation at the AACR meeting, Idera scientists summarized the results of several studies of IMO-2055 alone and in combination with ipilimumab in well-established preclinical models of bladder, colon and lung cancer. Results showed that intratumoral injections of IMO-2055 inhibited the growth of treated and distant tumors, as evaluated by tumor volume and histology. Compared to monotherapy with either agent, the combination regimen involving intratumoral injections of both agents demonstrated increased and sustained inhibition of treated and distant tumor growth. In addition, there were statistically significant increases in cytotoxic T cells against two antigens (AH1 and β-gal) expressed in treated and distant tumors, respectively, for the combination therapy versus monotherapy with either agent.

“In these preclinical models, intratumoral administration of a TLR 9 agonist enhanced the activity of a checkpoint inhibitor by inducing significantly greater anti-tumor immune responses against directly treated tumors and distant tumors representing models of metastatic cancer,” said Sudhir Agrawal, D.Phil., President of Research at Idera Pharmaceuticals. “Cancer immunotherapy represents an important and emerging area of oncology research, and combination regimens with agents such as IMO-2055 and ipilimumab or other checkpoint inhibitors may increase the ability to harness the body’s immune system to fight difficult-to-treat cancers in patients.”

“In addition to our ongoing and planned clinical development programs in genetically defined forms of B-cell lymphoma and rare diseases, Idera’s immuno-oncology research holds the promise of advancing cancer treatment for patients and driving value for the Company,” said Vincent Milano, Chief Executive Officer of Idera Pharmaceuticals. “With these compelling preclinical data, we are now assessing our options to advance a cancer immunotherapy program into clinical development. We look forward to unveiling those plans in 2015.”

The presentation, entitled “Intratumoral injection of IMO-2055, a novel Toll-like receptor 9 agonist, with ipilimumab induces a systemic tumor-specific immune response,” is available on Idera’s website at: http://www.iderapharma.com/our-science/key-presentations-and-publications. Ipilimumab is approved by the U.S. Food and Drug Administration for the treatment of unresectable or metastatic melanoma, and was developed by Bristol-Myers Squibb Company. The preclinical studies presented at the AACR meeting were conducted by scientists from Idera Pharmaceuticals.

About Toll-like Receptors and Idera’s Immuno-Oncology Research Program

Toll-like receptors (TLRs) play a central role in the innate immune system, the body’s first line of defense against invading pathogens, as well as damaged or dysfunctional cells including cancer cells. The innate immune system is also involved in activating the adaptive immune system, which marshals highly specific immune responses to target pathogens or tissue.

Cancer cells may exploit regulatory checkpoint pathways to avoid being recognized by the immune system, thereby shielding the tumor from immune attack. Checkpoint inhibitors such as agents targeting CTLA-4 or programmed cell death protein 1 (PD1) are designed to enable the immune system to recognize tumor cells. In this setting, a TLR 9 agonist may enhance the anti-tumor immune response by activating TLR signaling.

Based on the company’s proprietary chemistry-based discovery platform, Idera has designed and developed two synthetic oligonucleotide-based TLR 9 agonists, IMO-2055 and IMO-2125. In completed clinical trials, systemic administration of IMO-2055 was generally well tolerated as a monotherapy and in combination with other drugs in more than 300 patients with various types of cancers. In addition, systemic administration of IMO-2125 was generally well tolerated in about 80 patients with hepatitis C. Idera is currently conducting further preclinical research to evaluate the potential of IMO-2055 and IMO-2125 to enhance the anti-tumor activity of checkpoint inhibitors in cancer immunotherapy.

About Idera Pharmaceuticals   

Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic approach for the treatment of genetically defined forms of B-cell lymphoma and rare autoimmune diseases. Idera’s proprietary technology involves creating novel nucleic acid therapeutics designed to inhibit over-activation of Toll-like receptors (TLRs). In addition to its TLR programs, Idera is developing gene silencing oligonucleotides (GSOs) that it has created using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA. To learn more about Idera, visit www.iderapharma.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical fact, included or incorporated in this press release, including statements regarding the Company’s strategy, future operations, collaborations, intellectual property, cash resources, financial position, future revenues, projected costs, prospects, plans, and objectives of management, are forward-looking statements. The words “believes,” “anticipates,” “estimates,” “plans,” “expects,” “intends,” “may,” “could,” “should,” “potential,” “likely,” “projects,” “continue,” “will,” and “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Idera cannot guarantee that it will actually achieve the plans, intentions or expectations disclosed in its forward-looking statements and you should not place undue reliance on the Company’s forward-looking statements. There are a number of important factors that could cause Idera’s actual results to differ materially from those indicated or implied by its forward-looking statements. Factors that may cause such a difference include: whether results obtained in preclinical studies and clinical trials such as the preclinical data described in this release will be indicative of the results that will be generated in future clinical trials; whether products based on Idera’s technology will advance into or through the clinical trial process on a timely basis or at all and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if the Company’s products receive approval, they will be successfully distributed and marketed; whether the Company’s case resources are sufficient to fund the Company’s proposed programs and the Company’s operations for the period anticipated; and such other important factors as are set forth under the caption “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014. Although Idera may elect to do so at some point in the future, the Company does not assume any obligation to update any forward-looking statements and it disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

CONTACT: Investor and Media Contacts

         Robert Doody
         Vice President, Investor Relations
         and Corporate Communications
         484-639-7235
         rdoody@iderapharma.com

         Jim Baker
         Executive Director, Corporate Affairs
         617-679-5516
         jbaker@iderapharma.com

(CLNT) Receives $2.2 Million in Orders for Oil Refinery Parts and Equipment

WUXI, China, Dec. 2, 2014 — Cleantech Solutions International, Inc. (“Cleantech Solutions” or “the Company”) (NASDAQ: CLNT), a manufacturer of metal components and assemblies used in various clean technology and manufacturing industries and textile dyeing and finishing machines, today announced that on November 28, 2014 it received a purchase order for a total purchase price of RMB13.3 million (approximately $2.2 million) from a subsidiary of China Petroleum and Chemical Corporation (“Sinopec”).  The purchase order covers parts and equipment including heat exchangers, coolers, reboilers, condensers and prefractionating columns used in offshore oil refineries.

Pursuant to the purchase order, Cleantech Solutions has received an advance payment of approximately RMB2.0 million ($0.3 million), or 15% of the purchase price, will receive an additional 75% of the purchase price upon delivery, and will receive the remaining 10% within three months of delivery subject to successful installation and testing at the customer’s site.  The Company expects to deliver the equipment in March 2015.

“This purchase order represents the first order we have received from the oil and gas industry since we became a certified supplier of parts and equipment to Sinopec and China National Petroleum Corporation (“CNPC”).  We are pleased to extend our business into a new end market with favorable prospects for growth driven by environmental imperatives that encourage petroleum companies to reduce emissions and upgrade their facilities.  We are hopeful that this order will be the first of many significant orders from the oil and gas industry as our reputation for supplying precision products to this sector grows,” said Mr. Jianhua Wu, Chairman and CEO of Cleantech Solutions.

About Cleantech Solutions International

Cleantech Solutions is a manufacturer of metal components and assemblies, primarily used in clean technology and other industries and dyeing and finishing equipment for the textile industry and forging products, and a supplier of fabricated products and machining services to a range of clean technology customers.  The Company’s website is www.cleantechsolutionsinternational.com. Any information on the Company’s website or any other website is not a part of this press release.

Safe Harbor Statement

This release contains certain “forward-looking statements” relating to the business of the Company and its subsidiary and affiliated companies. These forward looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions. Such forward looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein referred to in this press release as anticipated, believed, estimated or expected. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including our ability to deliver and install the equipment referred to in this press release and to receive additional orders from the oil and gas industry and those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website, including factors described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-K for the year ended December 31, 2013 and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-Q for the quarter ended September 30, 2014.  All forward-looking statements attributable to the Company or to persons acting on its behalf are expressly qualified in their entirety by these factors other than as required under the securities laws. The Company does not assume a duty to update these forward-looking statements.

Company Contact:

Cleantech Solutions International, Inc.
Adam Wasserman, CFO
E-mail: adamw@cleantechsolutionsinternational.com
Web: www.cleantechsolutionsinternational.com

Elaine Ketchmere, CFA
Compass Investor Relations
Phone: +1-310-528-3031
E-mail: eketchmere@compass-ir.com

(MOLG) Largest Shareholder Makes Statement Supporting Company

KUALA LUMPUR, Malaysia, Dec. 2, 2014  — Mr. Vincent Tan, the largest shareholder of MOL Global, Inc. (Nasdaq:MOLG) today made the following statement in support of the company:

“MOL has encountered some difficulties over the last several days relating to an accounting error at its Vietnam subsidiary, a delayed earnings release and trading halt, and the departure of its CFO, Allan Wong. The timing of Allan’s departure for personal reasons which unfortunately coincided with the delay in the earnings release have resulted in some unhealthy speculation on the company’s financial numbers, and the stock price has been, in my view, unfairly punished.

“I have the utmost confidence in the management and MOL and none of these unfortunate events alters my very positive view of the underlying business of MOL. I have communicated my support to the management team at MOL, and while I know they are currently working very hard on addressing the issues that have arisen, I have encouraged them to continue to remain focused on executing their business plans.

“I also am very supportive of the board’s decision to implement a share buyback plan, as I believe that at the last closing price the stock is significantly undervalued.

Yours sincerely,

Tan Sri Dato’ Seri Vincent Tan Chee Yioun”

CONTACT: Tan Sri Vincent Tan
         Tel: 603-21491980
         Email: tsvt@berjaya.com.my

         MOL Global, Inc.
         Alvin Tan
         Tel: +65-6221-5680
         Email: IR@mol.com

         ICR, Inc.
         Calvin Jiang
         Tel: +1 (646) 405-4884
         Email: IR@mol.com

(ONNN) Board of Directors Approves $1 Billion Share Repurchase Program

ON Semiconductor (Nasdaq: ONNN), driving energy efficient innovations, today announced that its Board of Directors has approved a capital allocation policy under which the company intends to return approximately 80 percent of free cash flow less repayments of long-term debt to shareholders, subject to a variety of factors, including the company’s strategic plans, market and economic conditions, and Board of Directors’ discretion. ON Semiconductor defines free cash flow as net cash provided by operating activities less purchases of property, plant and equipment of the company and its consolidated subsidiaries.

The Board of Directors also approved a new share repurchase program under the new policy. Under the new share repurchase program, the company intends to repurchase approximately $1 billion worth of its common shares over a four year period, subject to the same factors and considerations described above. The new stock repurchase program is effective today and the $300 million stock repurchase program announced in August of 2012 has been terminated.

“The new capital allocation policy demonstrates ON Semiconductor’s strong commitment towards efficient use of capital and maximizing shareholder value,” said Keith Jackson, president and CEO of ON Semiconductor. “We believe that at current levels, our stock offers compelling value, and therefore the repurchase program should deliver substantial value to our shareholders. The long term outlook for our business remains strong, driven by a robust design win pipeline, and we are confident in our ability to generate approximately $300 million to $400 million of annual free cash flow on a sustained basis in the near to mid-term.”

Based on the closing price of the company’s common stock as of November 28 2014, the $1 billion repurchase program represents the potential repurchase of approximately 111 million shares or 25 percent of the weighted average diluted common shares outstanding at the end of the third quarter of 2014.

About ON Semiconductor

ON Semiconductor (Nasdaq: ONNN) is driving energy efficient innovations, empowering customers to reduce global energy use. The company offers a comprehensive portfolio of energy-efficient power and signal management, logic, discrete and custom solutions to help design engineers solve their unique design challenges in automotive, communications, computing, consumer, industrial, LED lighting, medical, military/aerospace and power supply applications. ON Semiconductor operates a responsive, reliable, world-class supply chain and quality program, and a network of manufacturing facilities, sales offices and design centers in key markets throughout North America, Europe, and the Asia Pacific regions. For more information, visit http://www.onsemi.com.

ON Semiconductor and the ON Semiconductor logo are registered trademarks of Semiconductor Components Industries, LLC. All other brand and product names appearing in this document are registered trademarks or trademarks of their respective holders. Although the company references its Web site in this news release, such information on the Web site is not to be incorporated herein.

Cautions regarding Forward-Looking Statements

This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included or incorporated in this document could be deemed forward-looking statements, particularly statements about the future financial performance of ON Semiconductor. These forward-looking statements are often characterized by the use of words such as “believes,” “estimates,” “expects,” “projects,” “may,” “will,” “intends,” “plans,” “should” or “anticipates,” or by discussions of strategy, plans or intentions. All forward-looking statements in this document are made based on information available to us as of the date of this release, our current expectations, forecasts, estimates, and assumptions, and involve risks, uncertainties and other factors that could cause results or events to differ materially from those expressed in the forward-looking statements. Among these factors are our revenues and operating performance, poor economic conditions and markets (including current financial conditions), effects of exchange rate fluctuations, the cyclical nature of the semiconductor industry, changes in demand for our products, changes in inventories at our customers and distributors, technological and product development risks, enforcement and protection of our intellectual property rights and related risks, risks related to the security of our information systems and secured network, availability of raw materials, electricity, gas, water and other supply chain uncertainties, our ability to effectively shift production to other facilities when required in order to maintain supply continuity for our customers, variable demand and the aggressive pricing environment for semiconductor products, our ability to successfully manufacture in increasing volumes on a cost-effective basis and with acceptable quality for our current products, competitor actions including the adverse impact of competitor product announcements, pricing and gross profit pressures, loss of key customers, order cancellations or reduced bookings, changes in manufacturing yields, control of costs and expenses and realization of cost savings and synergies from restructurings, significant litigation, risks associated with decisions to expend cash reserves for various uses such as debt prepayment, stock repurchases or acquisitions rather than to retain such cash for future needs, risks associated with acquisitions and dispositions (including from integrating and consolidating and timely filing financial information with the Securities and Exchange Commission for acquired businesses and difficulties encountered in accurately predicting the future financial performance of acquired businesses), risks associated with our substantial leverage and restrictive covenants in our debt agreements that may be in place from time to time, risks associated with our worldwide operations including foreign employment and labor matters associated with unions and collective bargaining arrangements as well as man-made and/or natural disasters affecting our operations and finances/financials, the threat or occurrence of international armed conflict and terrorist activities both in the United States and internationally, risks and costs associated with increased and new regulation of corporate governance and disclosure standards, risks related to new legal requirements and risks involving environmental or other governmental regulation. Information concerning additional factors that could cause results to differ materially from those projected in the forward-looking statements is contained in ON Semiconductor’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other of our filings with the Securities and Exchange Commission. If any of these trends, risks or uncertainties actually occurs or continues, our business, financial condition or operating results could be materially adversely affected, the trading prices of our securities could decline, our intentions with respect to our stock repurchase program and capital allocation policy may not be realized, and investors could lose all or part of their investment.

Readers are cautioned not to place undue reliance on forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any subsequent date and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made.

Additional Information about the New Stock Repurchase Plan and Where to Find It

For additional information, visit ON Semiconductor’s corporate website, www.onsemi.com, or for official filings visit the SEC website, www.sec.gov.

(OTIC) Patient Enrollment Target in Phase 2b Clinical Trial of OTO-104 in Meniere’s Disease

SAN DIEGO, Dec. 1, 2014 — Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced that the company has achieved target enrollment in its Phase 2b clinical trial of OTO-104 in patients with Ménière’s disease.

This prospective, randomized, double-blind, placebo-controlled study is designed to assess the efficacy and safety of OTO-104 for the treatment of Ménière’s disease in a total of 140 patients. In the Phase 2b clinical trial, patients are observed for up to four months following a single intratympanic (IT) injection of either OTO-104 or placebo. The primary endpoint, consistent with the previous Phase 1b clinical trial, is the reduction in vertigo frequency during Month 3 following treatment compared to a one month baseline period. The clinical trial has been designed and is being conducted to serve as one of two pivotal, single-dose efficacy trials that the company expects the FDA will require to support a New Drug Application (NDA) filing for treatment of Ménière’s disease.

“We would like to thank the patients for their participation, and the clinical investigators for their support in achieving our enrollment goal for this trial,” said David A. Weber, Ph.D., president and CEO of Otonomy. “A number of potential subjects are still completing the one month lead-in period of the trial, which could result in total enrollment that will exceed 140. We continue to expect results in the second quarter of 2015.”

About OTO-104

OTO-104, which has been granted Fast Track designation by the FDA, is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Ménière’s disease and other inner ear conditions. Otonomy has completed a randomized, prospective, double-blind, placebo-controlled, Phase 1b clinical trial of a single IT injection of OTO-104 in patients with Ménière’s disease. Results demonstrated that OTO-104 is well tolerated when administered as a single IT injection, and 12 mg of OTO-104 was associated with clinically meaningful improvements in both vertigo frequency and tinnitus compared to placebo three months after treatment. There were no serious adverse events observed during the clinical trial. A Phase 2b single-dose efficacy trial with approximately 140 Ménière’s disease patients is ongoing in the U.S. and Canada, with results expected in the second quarter of 2015. The company believes this trial will serve as one of two pivotal, single-dose efficacy trials required to support U.S. regulatory approval. OTO-104 is also being evaluated in a multiple-dose safety study in the United Kingdom in patients with Ménière’s disease, and the company expects the results of which will support regulatory filings in this indication.

About Ménière’s Disease

Ménière’s disease is a chronic condition characterized by acute vertigo attacks, tinnitus, fluctuating hearing loss and a feeling of aural fullness. Of these symptoms, the vertigo attacks are typically most troubling for patients since they disrupt daily activities and are difficult to anticipate and manage. In general, patients are diagnosed with unilateral Ménière’s disease in middle age and symptoms often continue for decades. Over time, the fluctuating hearing loss becomes permanent in many patients, and a subset of patients will develop symptoms in their second ear. According to the National Institute of Deafness and Other Communication Disorders, there are more than 600,000 patients diagnosed with Ménière’s disease in the United States. There is no known cure for Ménière’s disease and there are currently no FDA-approved drug treatments.

About Otonomy

Otonomy is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear. Otonomy’s proprietary technology provides sustained exposure of drugs to the middle and inner ear following a single intratympanic (IT) injection. Otonomy has three product candidates in development. AuriPro™ is an antibiotic that has completed Phase 3 clinical trials in pediatric patients with middle ear effusion at the time of tympanostomy tube placement surgery. OTO-104 is a steroid that is in the first of two pivotal clinical studies for the treatment of patients with Ménière’s disease. OTO-311 is an NMDA receptor antagonist in development as a treatment for tinnitus. For additional information, please visit www.otonomy.com.

Cautionary Note Regarding Forward Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, the expected enrollment and timing of the results for Otonomy’s single-dose Phase 2b clinical trial of OTO-104, Otonomy’s belief that the single-dose Phase 2b clinical trial of OTO-104 will serve as one of two pivotal, single-dose efficacy trials required to support an NDA filing for the treatment of Ménière’s disease and U.S. regulatory approval, the number of clinical trials with OTO-104 required by the FDA for U.S. regulatory approval, and the Company’s expectation that the multiple-dose safety study of OTO-104 in the United Kingdom in patients with Ménière’s disease will support regulatory filings in this indication. Forward-looking statements reflect the Company’s current views with respect to certain current and future events and are subject to various risks and uncertainties that could cause actual results to differ materially. Risks and uncertainties include, but are not limited to: expectations regarding clinical trial results for existing product candidates, future development of product candidates for additional indications, and future development of other product candidates; timing and likelihood of regulatory filings and approvals; expectations regarding adoption and use of product candidates by physicians; Otonomy’s ability to protect its intellectual property related to product candidates in the United States and throughout the world; Otonomy’s ability to manage operating expenses, capital requirements and additional financing needs; implementation of Otonomy’s business model and strategic plans for its business, products and technology; Otonomy’s dependence on third parties for development, manufacture and distribution of products; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in Otonomy’s Form 10-Q filed on November 12, 2014 with the Securities and Exchange Commission (the SEC), the final prospectus related to Otonomy’s initial public offering filed with the SEC on August 13, 2014, and Otonomy’s future reports to be filed with the SEC. The forward-looking statements in this press release are based on information available to Otonomy as of the date hereof. Otonomy disclaims any obligation to update any forward-looking statements, except as required by law.

CONTACT: Media Inquiries
         Canale Communications
         Heidi Chokeir, Ph.D.
         Vice President
         619.849.5377
         heidi@canalecomm.com

         Investor Inquiries
         Westwicke Partners
         Robert H. Uhl
         Managing Director
         858.356.5932
         robert.uhl@westwicke.com

(SANW) Files Patent for Unique Stevia Variety for Commercial Production

New variety possesses increased levels of Reb-A sweetener component and high plant productivity (yield) designed for the commercial production and processing market

FIVE POINTS, Calif., Dec. 1, 2014  — S&W Seed Company (Nasdaq: SANW) today announced it has filed a patent application with the U.S. Patent and Trademark Office for stevia plant variety “SW107.”  Variety SW107 exhibits increased concentrations of Reb-A sweetener, higher leaf mass production and an improved taste profile that has little or no aftertaste. SW107 has been bred to address commercial processing markets in North America, South America, and other regions of the world that have climates suitable for it.

Companies producing consumer food products, as well as ingredient manufacturers, recognize the value of stevia as an all-natural sweetener in beverage, dairy, baking and snack products. Stevia’s health benefits include zero calories and minimal glycemic impact and stability when heated. Since the primary sweetener used in stevia-based products, Reb A, comes 100% from agricultural sources, the Company believes that improved stevia varieties, like SW107, with increased yield and Reb A content will be very desirable commercially.

The Company believes SW107 is well qualified to be successful in the commercial market. SW107 has a number of differentiating factors, including enhanced leaf yield, Reb-A output, and taste profile, as well as plant vigor that includes superior overwintering and later flowering attributes compared with the majority of the plant population from which the line was derived. In field trials throughout the western United States, SW107 yielded approximately 40% more leaf, 60% more Reb-A content, and more than a 100% increase in the Reb-A to stevioside ratio, as compared to test samples from stevia varieties now in mainstream production. S&W believes these results, coupled with an improved aftertaste profile, mean that SW107 will be economically attractive to stevia farmers and to the commercial volume stevia processing community.  With the filing of this patent application, the Company will begin seeking agreements with consumer products companies, ingredient manufacturers and stevia mass processors.

Mark Grewal, chief executive officer of S&W Seed Company, commented, “This patent application marks a significant milestone in our stevia development program. With the huge growth in demand for stevia in the last five years since we entered the industry, food manufacturers and processors have expressed a desire for reliable sources of stevia leaf production outside of China. Due to the higher leaf mass of SW107, which adds to yield, the high Reb-A percentage, and its improved taste and plant vigor characteristics, we believe SW107 addresses many of the economic challenges that farmers and producers in North and South America have faced to date.”

Variety SW107 was classically bred from germplasm that is proprietary to S&W’s stevia program that first commenced in 2009 under the direction of Dr. Clint Shock, who is an internationally recognized expert on stevia. S&W’s stevia research and development team has crossed hundreds of lines of stevia plants, many of which were collected over many years, with a goal of developing stevia varieties that have unique properties for commercialization. The Company is optimistic that SW107 will be followed by other promising varieties.  S&W’s research and development team hopes to develop other new varieties that have distinctly different sets of plant attributes and can address other market needs.  SW107 initially is targeted at North and South America, where stevia plant production has been somewhat limited.

To date, stevia production and extraction has largely been based in China and, to a lesser extent, South America. SW107 initially is targeted to be produced in North America and South America, where there have been insignificant commercial quantities grown due to farming economics. S&W believes SW107 will facilitate the growth of stevia in mass commercial quantities in these regions due to its high plant productivity (yield) and enhanced levels of Reb-A to extract.

About S&W Seed Company
Founded in 1980, S&W Seed Company is a global agricultural company, headquartered in the Central Valley of California. The company is the largest producer of non-dormant alfalfa seed varieties in the world, with production operations in the San Joaquin and Imperial Valleys of California, as well as in South Australia. The company has worldwide sales and distribution through both a direct sales force as well as dealer-distributors.  The company’s proprietary varieties are designed to meet the shifting needs of farmers that require high performance in poor and highly saline soil conditions and have been verified over decades of university-sponsored trials.  Additionally, the company is utilizing its research and breeding expertise to develop and produce U.S.-based stevia leaf.  Stevia is an all-natural, zero calorie sweetener for the food and beverage industry. For more information, please visit www.swseedco.com.

Safe Harbor Statement
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may,” “future,” “plan” or “planned,” “will” or “should,” “expected,” “anticipates,” “draft,” “eventually” or “projected.” You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors and other risks identified in the Company’s 10-K for the fiscal year ended June 30, 2014, and other filings made by the Company with the Securities and Exchange Commission.

(CANF) Published: Potential Breakthrough for Prevention of Neuropathic Pain by CF101

PETACH TIKVA, Israel, Dec. 1, 2014 — Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported newly published scientific findings conducted by St. Louis University researchers, Daniela Salvemini and colleagues in collaboration with Dr. Jacobson from the National Institutes of Health (NIH), on the prevention of neuropathic pain by CF101, generically known as IB-MECA. According to the research, the latter binds with high affinity to the A3 adenosine receptor and via specific mechanistic pathways significantly reduces neuropathic pain in animal models. Can-Fite CEO Dr. Pnina Fishman commented on these findings, stating, “It is very interesting that our drugs have additional well-defined clinical application in the field of neuropathic pain which is an unmet need. The study indicates some compelling results that relate to our CF101 and CF102 drugs. Former studies from the same group also showed similar data utilizing CF102, known as Cl-IB-MECA. In addition, this group showed earlier that CF101 prevents chemotherapy-induced peripheral neuropathy in pre-clinical studies. We believe that the A3 adenosine platform technology that we have been developing over the past decade and the excellent safety profile of the drugs has the potential to yield a unique therapy for this patient population.”

While Can-Fite holds an exclusive worldwide license from NIH for clinical development of IB-MECA and Cl-IB-MECA, these compounds may be used for basic research purposes in the lab.

About Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer and inflammatory diseases. The Company’s CF101 is in Phase II/III trials for the treatment of psoriasis and the Company is preparing for a Phase III CF101 trial for rheumatoid arthritis. Can-Fite’s liver cancer drug CF102 is commencing Phase II trials and has been granted Orphan Drug Designation by the U.S. Food and Drug Administration. CF102 has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. These drugs have an excellent safety profile with experience in over 1,200 patients in clinical studies to date. For more information please visit: www.can-fite.com

Forward-Looking Statements

This press release may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by Can-Fite with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of Can-Fite’s authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Can-Fite’s actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Can-Fite’s actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements, including, but not limited to, the factors summarized in Can-Fite’s filings with the SEC and in its periodic filings with the TASE.  In addition, Can-Fite operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control.  Can-Fite does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.

Contact

Can-Fite BioPharma
Motti Farbstein
info@canfite.com
+972-3-9241114

(ISR) Cesium-131 Therapy Stops Brain Cancers from Recurring

RICHLAND, WA, United States, via ETELIGIS INC., 12/01/2014 – – IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in brachytherapy and medical isotope applications, today announced the striking results of a study of brain cancer patients treated with IsoRays Cesium-131 internal radiation (brachytherapy) cancer therapy. The findings of the study, conducted by researchers at Barrow Neurological Institute, were presented at the November 2014 annual meeting of the Society for Neuro-Oncology in Miami, Florida.

The Barrow study reported on 27 patients who had a variety of deadly brain cancers, including high grade gliomas, high grade meningiomas, and brain metastases. The patients had received an average of 2 and as many as 4 extensive earlier treatments that had failed, resulting in a recurrence of their cancers in the same locations where treatment had previously been applied.

IsoRay Chairman and CEO Dwight Babcock commented, Cancers that recur in the brain pose major problems. They have shown a resistance to the standard therapies of surgery and conventional radiation. Given the confined volume of the interior of the skull, the impact of brain tumors is debilitating. Expanding cancerous masses compress brain matter and nerves originating in the brain leading to significant and life-altering complications.

Oncologists at the prestigious Barrow Neurological Institute employed a technique developed by GammaTile, LLC that provides an intensive dose of Cesium-131-based radiation in tandem with surgical removal of these malignant growths. Following surgical removal of the tumor tissue, Cesium-131 was delivered to the targeted brain tissue using a modular, pre-commercial biocompatible carrier system that provided custom-tailored implants for each patient.

Barrow neuro-oncologist Dr. Christopher Dardis presented the data to an audience of neuro-oncologists specialists who manage the treatment of brain cancer patients. According to Dr. Dardis presentation, the patients who were treated with the new approach using Cesium-131 fared better than they had using earlier, conventional treatment. In fact, 26 of the 27 patients (96%) had not experienced a recurrence of the treated cancer within the treated bed during the follow-up period.

Barrow Neurological Institute is among the worlds foremost brain cancer research and treatment sites. The study team was led by radiation oncologist Dr. David Brachman and neurosurgeon Dr. Peter Nakaji, both internationally renowned and respected in the field of brain cancer treatment.

Dr. Brachman, who serves as Chief Technology Officer at GammaTile, LLC, said: As a rule, we dont necessarily think that the second or third line treatment would work better than the first-line treatment. But this seems to be the case here. Based on these outcomes, this new therapy successfully treated patients who failed conventional therapies and we believe that it could help many other patients.

IsoRay CEO Dwight Babcock commented, “We are extremely excited to see that Cesium-131 isotope seeds continue to perform so well against aggressive cancers throughout the body, including a variety of brain cancers as shown in this study. This further confirms other peerreviewed results showing Cesium-131 can have a very favorable impact on local control, especially for cancers that have shown a tendency to recur at the site of surgery. We remain committed to helping patients afflicted with these horrible cancers and enhancing their quality of life. The message is clear and the medical community is becoming increasingly aware of the innovative alternative our Cesium-131 products offer to cancer patients.

IsoRays various products, including Cesium-131 seeds, sutured seeds, stranded mesh and the GliaSite radiation therapy system, give physicians the ability to directly place a specified dosage of radiation in areas where cancer is most likely to remain after completion of a tumor removal or by placing seeds within the prostate. The ability to precisely place a specified dose of radiation means there is less likelihood for damage to occur to healthy surrounding tissue compared to other alternative treatments. IsoRays cancer fighting products diminish the ability of the tumor to recur, resulting in important benefits for patients in longevity as well as quality of life.

IsoRay is the exclusive manufacturer of Cesium-131. The pioneering brachytherapy therapy is one of the most significant advances in internal radiation therapy in 20 years. Cesium-131 allows for the precise treatment of many different cancers because of its unrivaled blend of high energy and its 9.7 day half-life (its unequaled speed in giving off therapeutic radiation).

In addition to its CMS codes, Cesium-131 is FDA-cleared and holds a CE mark for international sales in seed form for the treatment of brain cancer, prostate cancer, lung cancer, ocular melanoma cancer, colorectal cancer, gynecologic cancer, head and neck cancer and other cancers throughout the body. The treatment can be deployed using several delivery methods including single seed applicators, implantable strands and seed sutured mesh. IsoRay also sells several new implantable devices, including the GliaSite radiation therapy system.

About IsoRay:

IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of GliaSite and Cesium-131 by visiting www.isoray.com. Join us on Facebook/Isoray. Follow us on Twitter @Isoray.

Safe Harbor Statement:

Statements in this news release about IsoRay’s future expectations, including: the advantages of our products and their delivery systems, whether IsoRay will be able to continue to expand its base beyond prostate cancer, whether sales of our products will continue at historic levels or increase, whether the use of our products will increase or continue, whether we will continue to receive support from industry leaders, whether awareness of our products in the medical community will continue or increase, whether future studies of treatment of various cancers using our products will have favorable results, and all other statements in this release, other than historical facts, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether additional studies are released and support the conclusions of past studies, whether ongoing patient results with our products are favorable and in line with the conclusions of clinical studies and initial patient results, patient results achieved when our products are used for the treatment of cancers and malignant diseases beyond prostate, successful completion of future research and development activities, whether we, our distributors and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell and use our products in its various forms, continued compliance with ISO standards as audited by BSI, the success of our sales and marketing efforts, changes in reimbursement rates, changes in laws and regulations applicable to our products, and other risks detailed from time to time in IsoRay’s reports filed with the SEC.

CONTACT:

IsoRay Medical

Info@Isoray.com

(509) 375-1202

Worldwide Financial

Info@wwfinancial.com

(954) 360-9998

(FLL) Announces the Appointment of Daniel R. Lee as Chief Executive Officer

Full House Resorts, Inc. (NASDAQ:FLL), a developer and manager of gaming facilities, today announced that it has reached a favorable agreement with a group of shareholders, enhancing expertise to its management team and board.

Under the terms of the agreement, the Board has been increased from five to nine members and the Company accepted the resignations of Andre M. Hilliou and Mark J. Miller as directors and entered into Separation Agreements with respect to their employment. To fill the resulting six vacancies, W.H. Baird Garrett, Raymond Hemmig, Ellis Landau, Daniel R. Lee, Bradley M. Tirpak and Craig W. Thomas have been appointed to serve as directors, each subject to normal and customary regulatory approvals. Mr. Lee will replace Mr. Hilliou as the Company’s Chief Executive Officer.

Mr. Lee was previously the Chairman and Chief Executive Officer of Pinnacle Entertainment, a large regional casino company. In that role, he oversaw successful properties in each of the principal markets where Full House operates. Prior thereto, during the 1990s, he was the Chief Financial Officer and Senior Vice President of Finance and Development of Mirage Resorts. In various roles, he has participated in the development of numerous major casinos throughout his career, all of which have been successful. These include L’Auberge and the soon-to-open Golden Nugget in Lake Charles, Louisiana; River City and Lumiere Place in St. Louis, Missouri; Casino Magic in Neuquen, Argentina; Bellagio, Treasure Island and Monte Carlo in Las Vegas; and The Borgata in Atlantic City, New Jersey. He worked on Wall Street earlier in his career, as a Chartered Financial Analyst specializing in the casino and hotel industries. Mr. Lee has a Bachelors’ degree in Hotel Administration and a Masters degree in Business Administration, both from Cornell University.

In connection with his appointment as the Company’s Chief Executive Officer, the Company’s compensation committee of the board of directors approved the grant to Mr. Lee of a stock option to purchase 943,834 shares of the Company’s common stock at an exercise price per share equal to the closing price of Company’s common stock on the grant date. Mr. Lee’s option is scheduled to vest over a four-year period, with 25% vesting on the first anniversary of the grant date and the remaining 75% vesting in substantially equal installments over the following three years (subject to full or partial accelerated vesting on a qualifying termination of employment or a change in control of the Company). The stock option was granted as a material component of Mr. Lee’s compensation and decision to enter into employment with the Company and was granted as an employment inducement award pursuant to NASDAQ Listing Rule 5635(c)(4).

As part of the agreement, Messrs. Lee, Tirpak and Thomas have withdrawn their solicitation statement calling for a special meeting of shareholders and will cease all further solicitation efforts. The settlement document will be filed with the Securities and Exchange Commission.

The Company believes that the settlement agreement is in the best interests of stockholders and resolves the issues raised by the concerned stockholder group in a favorable manner for all parties. The Company looks forward to working with the new members of the Board and management in its continued efforts to maximize stockholder value. Accordingly, and with the concurrence of the reconstituted board, the Company looks forward to continuing to work with its financial advisors to evaluate all strategic alternatives for the company.

“I would like to thank the incumbent Full House Board for working with us to position the Company for future success,” stated Full House’s new CEO, Daniel R. Lee. “I would also like to thank Andre and Mark for their many years of service with the Company and wish them well in their future endeavors. Finally, I look forward to meeting all of the Full House employees and to working together to make Full House Resorts into a strong and successful company building value for shareholders.”

About Full House Resorts, Inc.

Full House owns, develops and manages gaming facilities throughout the country. The Rising Star Riverboat Casino in Rising Sun, Indiana has 35,000 square feet of gaming space with 940 slot and video poker machines and 30 table games. The property includes 294 hotel rooms, a pavilion with five food and beverage outlets, an 18-hole Scottish links golf course and a large, multi-purpose Grand Theater for concerts and performance events as well as meetings and conventions. The Silver Slipper Casino in Hancock County, Mississippi, has 37,000 square feet of gaming space with almost 1,000 slot and video poker machines, 26 table games, and the only live Keno game on the Gulf Coast. The property includes a fine dining restaurant, buffet, quick service restaurant and two casino bars. Stockman’s Casino in Fallon, Nevada has 8,400 square feet of gaming space with approximately 265 gaming machines, four table games and a keno game. The Company also operates the Grand Lodge Casino at the Hyatt Regency Lake Tahoe Resort, Spa and Casino in Incline Village, Nevada on the north shore of Lake Tahoe under a lease agreement with the Hyatt organization. Further information about Full House Resorts can be viewed on its website at www.fullhouseresorts.com.

Forward-looking Statements

Some of the statements made in this release are forward-looking statements. These forward-looking statements are based upon Full House’s current expectations and projections about future events and generally relate to Full House’s plans, objectives and expectations for Full House’s business. Although Full House’s management believes that the plans and objectives expressed in these forward-looking statements are reasonable, the outcome of such plans, objectives and expectations involve risks and uncertainties including without limitation, regulatory approvals, including the ability to maintain a gaming license in Indiana, Nevada and Mississippi, financing sources and terms, integration of acquisitions, competition and business conditions in the gaming industry, including competition from Ohio casinos. Additional information concerning potential factors that could affect Full House’s financial condition and results of operations is included in the reports Full House files with the Securities and Exchange Commission, including, but not limited to, its Form 10-K for the most recently ended fiscal year.